These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 33368377)

  • 1. Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators.
    Amin OE; Colbeck EJ; Daffis S; Khan S; Ramakrishnan D; Pattabiraman D; Chu R; Micolochick Steuer H; Lehar S; Peiser L; Palazzo A; Frey C; Davies J; Javanbakht H; Rosenberg WMC; Fletcher SP; Maini MK; Pallett LJ
    Hepatology; 2021 Jul; 74(1):55-71. PubMed ID: 33368377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B.
    Daffis S; Balsitis S; Chamberlain J; Zheng J; Santos R; Rowe W; Ramakrishnan D; Pattabiraman D; Spurlock S; Chu R; Kang D; Mish M; Ramirez R; Li L; Li B; Ma S; Hung M; Voitenleitner C; Yon C; Suresh M; Menne S; Cote P; Delaney WE; Mackman R; Fletcher SP
    Hepatology; 2021 Jan; 73(1):53-67. PubMed ID: 32246499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follicular Helper T (T
    Ayithan N; Tang L; Tan SK; Chen D; Wallin JJ; Fletcher SP; Kottilil S; Poonia B
    Front Immunol; 2021; 12():735913. PubMed ID: 34512670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells.
    Li L; Barry V; Daffis S; Niu C; Huntzicker E; French DM; Mikaelian I; Lanford RE; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):912-921. PubMed ID: 29247724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B.
    Gane EJ; Kim HJ; Visvanathan K; Kim YJ; Nguyen AH; Wallin JJ; Chen DY; McDonald C; Arora P; Tan SK; Gaggar A; Roberts SK; Lim YS
    Hepatology; 2021 Oct; 74(4):1737-1749. PubMed ID: 33704806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.
    Boni C; Janssen HLA; Rossi M; Yoon SK; Vecchi A; Barili V; Yoshida EM; Trinh H; Rodell TC; Laccabue D; Alfieri A; Brillo F; Fisicaro P; Acerbi G; Pedrazzi G; Andreone P; Cursaro C; Margotti M; Santoro R; Piazzolla V; Brunetto MR; Coco B; Cavallone D; Zhao Y; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Massetto B; Fung S; Ahn SH; Ma X; Mangia A; Ferrari C
    Gastroenterology; 2019 Jul; 157(1):227-241.e7. PubMed ID: 30930022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.
    Mackman RL; Mish M; Chin G; Perry JK; Appleby T; Aktoudianakis V; Metobo S; Pyun P; Niu C; Daffis S; Yu H; Zheng J; Villasenor AG; Zablocki J; Chamberlain J; Jin H; Lee G; Suekawa-Pirrone K; Santos R; Delaney WE; Fletcher SP
    J Med Chem; 2020 Sep; 63(18):10188-10203. PubMed ID: 32407112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection.
    Shao X; Ma J; Jia S; Yang L; Wang W; Jin Z
    Front Cell Infect Microbiol; 2017; 7():472. PubMed ID: 29181338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Selective TLR8 Agonist Selgantolimod Induces Multiple Immune Cell Responses in Humans.
    Ayithan N; Ghosh A; Dwivedi A; Wallin JJ; Tan SK; Chen D; Kottilil S; Poonia B
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.
    Boni C; Vecchi A; Rossi M; Laccabue D; Giuberti T; Alfieri A; Lampertico P; Grossi G; Facchetti F; Brunetto MR; Coco B; Cavallone D; Mangia A; Santoro R; Piazzolla V; Lau A; Gaggar A; Subramanian GM; Ferrari C
    Gastroenterology; 2018 May; 154(6):1764-1777.e7. PubMed ID: 29378197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
    Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8
    Xun Z; Lin J; Yu Q; Liu C; Huang J; Shang H; Guo J; Ye Y; Wu W; Zeng Y; Wu S; Xu S; Chen T; Chen J; Ou Q
    Cell Mol Immunol; 2021 Feb; 18(2):461-471. PubMed ID: 33432062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy.
    Pal S; Nandi M; Dey D; Chakraborty BC; Shil A; Ghosh S; Banerjee S; Santra A; Ahammed SKM; Chowdhury A; Datta S
    Aliment Pharmacol Ther; 2019 May; 49(10):1346-1359. PubMed ID: 30982998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.
    Li CZ; Hu JJ; Xue JY; Yin W; Liu YY; Fan WH; Xu H; Liang XS
    World J Gastroenterol; 2014 Jul; 20(28):9486-96. PubMed ID: 25071343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor 7 agonist, GS-986, is an immune-stimulant inducing follicular helper T cells and expanding HBs antigen-specific B cells in vitro.
    Mori T; Yoshio S; Yoshikawa S; Tsustui Y; Sakata T; Yoshida Y; Sakamoto Y; Kawai H; Osawa Y; Yamazoe T; Aoki Y; Fletcher SP; Kanto T
    Liver Int; 2023 Jun; 43(6):1213-1224. PubMed ID: 37029645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-α-2a antiviral therapy.
    Deng G; Ge J; Liu C; Pang J; Huang Z; Peng J; Sun J; Hou J; Zhang X
    Clin Res Hepatol Gastroenterol; 2017 Sep; 41(4):386-398. PubMed ID: 28236535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Alterations of IFN-γ and IL-4 of peripheral blood T cells in patients with chronic HBV infection].
    Li M; Sun X; Zhou Z; Zhang X; Jin S; Gao Y; Gao Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Feb; 32(2):240-4. PubMed ID: 26927386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery of circulating CD56
    Liu N; Liu B; Zhang L; Li H; Chen Z; Luo A; Chen M; Peng M; Yin W; Ren H; Hu P
    Int Immunopharmacol; 2018 Sep; 62():59-66. PubMed ID: 29990695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects.
    Reyes M; Lutz JD; Lau AH; Gaggar A; Grant EP; Joshi A; Mackman RL; Ling J; Tan SK; Ayithan N; Daffis S; Woo J; Wu P; Lam T; Fletcher SP; Kottilil S; Poonia B; Gane EJ; Mathias A; German P
    Antivir Ther; 2020; 25(3):171-180. PubMed ID: 32667286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association among cytokine profiles of innate and adaptive immune responses and clinical-virological features in untreated patients with chronic hepatitis B.
    Gu Y; Lian Y; Zheng Q; Huang Z; Gu L; Bi Y; Li J; Huang Y; Wu Y; Chen L; Huang Y
    BMC Infect Dis; 2020 Jul; 20(1):509. PubMed ID: 32664850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.